Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biosortia Pharmaceuticals has launched three new oncology research projects using microbial compounds.
Subscribe to our email newsletter
The projects will investigate the company’s libraries of consortia microbial compounds for potential drug discovery in pediatric cancer (neuroblastoma), liver cancer (Hepatitis C virus) and an alternative approach to combat tumor growth by stimulating a patient’s immune responses (immuno-oncology).
Researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) and The Research Institute at Nationwide Children’s Hospital will carry out the research in collaboration with Biosortia.
The Ohio State University’s cancer institutional review board chairman William Carson will focus on new therapeutics to stimulate a patient’s immune response.
The study aims to identify how inhibition of MDSC and augmentation T cell and NK cells effector functions could improve a patient’s immune response to cancer. The study’s outcome may help in developing alternative approaches for addressing cancerous tumor growth.
Ohio State professor of chemistry Zucai Suo will research natural product inhibitors to treat liver cancer and viral infections.
Ruoning Wang, a childhood cancer and blood disease researcher at Nationwide Children’s Hospital will carry out a study targeting pediatric cancer and the proliferation of neuroblastoma through characteristic mitochondria oxidation.
Biosortia chief scientific officer Guy Carter said: "Doctors Wang, Suo and Carson bring extraordinary expertise and a diversity of focus.
"We are encouraged to be working with them as we strive to deliver targeted therapies that will bring better outcomes in the fight against cancer."